CompletedPhase 2NCT02318784
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Studying Neuroendocrine carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SCRI Development Innovations, LLC
- Principal Investigator
- David Spigel, M.D.SCRI Development Innovations, LLC
- Intervention
- Carfilzomib(drug)
- Enrollment
- 62 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2021
Study locations (10)
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- Florida Hospital Cancer Institute, Orlando, Florida, United States
- Florida Cancer Specialists - North, St. Petersburg, Florida, United States
- Ingalls Cancer Research Center, Harvey, Illinois, United States
- Research Medical Center, Kansas City, Missouri, United States
- Oncology Hematology Care, INC., Cincinnati, Ohio, United States
- Spartanburg Regional Medical Center/Gibbs Cancer Center, Spartanburg, South Carolina, United States
- Tennessee Oncology PLLC, Nashville, Tennessee, United States
- Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Collaborators
Amgen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02318784 on ClinicalTrials.govOther trials for Neuroendocrine carcinoma of pancreas
Additional recruiting or active studies for the same condition.